Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.19 USD | +0.16% |
|
-3.13% | -33.15% |
Jul. 01 | Health Catalyst, Inc.(NasdaqGS:HCAT) added to Russell 3000E Index | CI |
Jul. 01 | Health Catalyst, Inc.(NasdaqGS:HCAT) added to Russell Microcap Index | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Software
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.15% | 365M | C | ||
-3.06% | 256B | B | ||
-17.00% | 60.79B | B- | ||
+3.19% | 60.22B | B | ||
+1.80% | 53.42B | A- | ||
+10.86% | 45.01B | C | ||
+1.06% | 36.74B | B | ||
-8.72% | 28.92B | B | ||
+117.82% | 28.56B | - | ||
+6.57% | 22.33B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HCAT Stock
- Ratings Health Catalyst, Inc.